Evidence map›Paper›PMID 40973568›Full record

ArticleClinical imaging2025

The role of PSMA PET/CT in identifying benign and malignant intracranial lesions in patients with prostate cancer.

Caitlin Deffler, Ashkan Eighaei Sedeh, Ellen Leitman, Thomas S C Ng, David Z Chow, Umar Mahmood, Pedram Heidari, Nathaniel Mercaldo, Shadi A Esfahani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Caitlin DefflerDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: cedeffler@outlook.com.
Ashkan Eighaei SedehDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: ashy19923@gmail.com.
Ellen LeitmanDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: aleitman@mgb.org.
Thomas S C NgDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: sheung.ng@mgh.harvard.edu.
David Z ChowDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: david.chow@mgh.harvard.edu.
Umar MahmoodDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: umahmood@mgh.harvard.edu.
Pedram HeidariDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: heidari.pedram@mgh.harvard.edu.
Nathaniel MercaldoDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: nmercaldo@mgb.org.
Shadi A EsfahaniDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: esfahani.shadi@mgh.harvard.edu.

Funding

Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA259626
6 · The paper itself

Abstract

purposeTo evaluate the ability of prostate-specific membrane antigen (PSMA) PET/CT to detect and characterize intracranial lesions in patients with prostate cancer (PCa), using brain MRI as a gold standard method.

methodsIn this retrospective single-center study, standard-of-care

resultsOf 1482 reviewed PCa patients, 141 with available brain MRI within six months of PSMA PET/CT were included. The estimated incidence rate of brain metastasis was 1.1 % (17/1482; Exact 95 % CI: 0.7-1.83), using brain MRI. PSMA PET/CT had a sensitivity of 81.2 % (95 % CI: 54.4-96.0), a specificity of 93.6 % (95 % CI: 87.8-97.2), a PPV of 61.9 % (95 % CI: 44.4-76.8), and an NPV of 97.5 % (95 % CI: 93.3-99.1) for detecting at least one metastatic PCa lesion as confirmed by MRI. Although not statistically significant, the mean SUV

conclusionIntracranial uptake on PSMA PET/CT may require further clinical and imaging correlation for accurate characterization.

Indexed as

Brain NeoplasmsPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overAntigens, SurfaceGlutamate Carboxypeptidase IIHumansMagnetic Resonance ImagingMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesSensitivity and SpecificityAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticalsBrain metastasisIntracranial lesionsPET/CTProstate cancerProstate-specific membrane antigen

Identifiers

PMID40973568
PMCPMC13060774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.